HomeCompareRLFTD vs GBDC

RLFTD vs GBDC: Dividend Comparison 2026

RLFTD yields 49.02% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GBDC wins by $20.48M in total portfolio value· pulled ahead in Year 6
10 years
RLFTD
RLFTD
● Live price
49.02%
Share price
$4.08
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$374.5K
Annual income
$74,708.98
Full RLFTD calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — RLFTD vs GBDC

📍 GBDC pulled ahead of the other in Year 6

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRLFTDGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RLFTD + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RLFTD pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RLFTD
Annual income on $10K today (after 15% tax)
$4,166.67/yr
After 10yr DRIP, annual income (after tax)
$63,502.63/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, GBDC beats the other by $13,919,621.12/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RLFTD + GBDC for your $10,000?

RLFTD: 50%GBDC: 50%
100% GBDC50/50100% RLFTD
Portfolio after 10yr
$10.61M
Annual income
$8,262,721.41/yr
Blended yield
77.86%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

RLFTD
No analyst data
Altman Z
-12.4
Piotroski
5/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RLFTD buys
0
GBDC buys
0
No recent congressional trades found for RLFTD or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRLFTDGBDC
Forward yield49.02%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$374.5K$20.85M
Annual income after 10y$74,708.98$16,450,733.83
Total dividends collected$297.4K$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: RLFTD vs GBDC ($10,000, DRIP)

YearRLFTD PortfolioRLFTD Income/yrGBDC PortfolioGBDC Income/yrGap
1$15,602$4,901.96$12,492$1,791.70+$3.1KRLFTD
2$23,842$7,147.68$16,527$3,160.58+$7.3KRLFTD
3$35,719$10,208.01$23,588$5,904.90+$12.1KRLFTD
4$52,512$14,292.70$37,141$11,901.65+$15.4KRLFTD
5$75,825$19,637.72$66,205$26,463.38+$9.6KRLFTD
6← crossover$107,634$26,501.16$137,452$66,612.65$29.8KGBDC
7$150,326$35,157.45$342,372$195,298.53$192.0KGBDC
8$206,739$45,889.95$1,053,292$686,954.33$846.6KGBDC
9$280,193$58,982.29$4,111,439$2,984,416.95$3.83MGBDC
10$374,515$74,708.98$20,849,974$16,450,733.83$20.48MGBDC

RLFTD vs GBDC: Complete Analysis 2026

RLFTDStock

Relief Therapeutics Holding AG, a biopharmaceutical company, provides patients with therapeutic relief from serious diseases with high unmet medical need in Switzerland, rest of Europe, North America, and internationally. The company focuses on clinical-stage programs based on molecules with a history of clinical use and either initial human activity or efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action for respiratory indications, which is in Phase 3 clinical trials for treating COVID-19-induced acute respiratory distress syndrome and moderate to severe COVID-19 lung injury; in Phase 1 clinical trial for the treatment of patients with acute lung injury in other intensive care unit; and in Phase 2 clinical trial for the treatment of pulmonary sarcoidosis. The company is also developing ACER-001, a proprietary powder formulation of sodium phenylbutyrate, which has completed Phase 3 clinical trial for urea cycle disorders; and in Phase 1 clinical trial for the treatment of maple syrup urine disease. In addition, it is developing APR-TD011, a spray-formulated hypotonic acid-oxidizing solution, which is in Phase 2 clinical trial for treating epidermolysis bullosa. The company was founded in 2013 and is based in Geneva, Switzerland.

Full RLFTD Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this RLFTD vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RLFTD vs SCHDRLFTD vs JEPIRLFTD vs ORLFTD vs KORLFTD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.